| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 08/30/2001 | US20010018050 Administering protein C; avoiding bleeding, toxicity and side effects of anticoagulant agents |
| 08/30/2001 | DE10008329A1 New aminosulfonyl-biphenyl derivatives are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, arteriosclerosis, inflammation or angina pectoris |
| 08/30/2001 | CA2401013A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 08/30/2001 | CA2400485A1 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
| 08/30/2001 | CA2400435A1 Novel compounds |
| 08/30/2001 | CA2400434A1 Novel compounds |
| 08/30/2001 | CA2400293A1 Novel compounds |
| 08/30/2001 | CA2400040A1 Integrin antagonists |
| 08/30/2001 | CA2399211A1 Foam-forming wound dressing |
| 08/30/2001 | CA2399018A1 Aminosulfonylbiphenyl derivatives |
| 08/30/2001 | CA2398275A1 Human polynucleotides, polypeptides, and antibodies |
| 08/29/2001 | EP1127884A1 Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them |
| 08/29/2001 | EP1127880A2 Phenylacetic acid derivatives substituted by a heterocycle and their use as A-II antagonists and as inhibitors of smooth muscle cell proliferation |
| 08/29/2001 | EP1127577A2 Ligand for the c-kit receptor and methods of use thereof |
| 08/29/2001 | EP1127151A2 Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors |
| 08/29/2001 | EP1127123A2 Cell surface glycoproteins |
| 08/29/2001 | EP1127117A1 Opg fusion protein compositions and methods |
| 08/29/2001 | EP1127071A1 Compounds with growth hormone releasing properties |
| 08/29/2001 | EP1127051A2 Tricyclic pyrazole derivatives |
| 08/29/2001 | EP1126870A2 Use of vegf-c or vegf-d gene or protein to prevent restenosis |
| 08/29/2001 | EP1126858A1 Production of a biological factor and creation of an immunologically privileged environment using genetically altered sertoli cells |
| 08/29/2001 | EP1126854A1 Benzoazepines and analogs thereof useful as growth hormone secretagogues |
| 08/29/2001 | EP1126852A1 Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| 08/29/2001 | EP1126842A2 Inhibition of the formation of vascular hyperpermeability |
| 08/29/2001 | EP1126839A1 Substituted phenethylsulfones and method of reducing tnf alpha levels |
| 08/29/2001 | EP1126838A1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 08/29/2001 | EP1126836A1 Benzamide potassium channel inhibitors |
| 08/29/2001 | EP0904299B1 Synthetic polysaccharides, method for preparing same and pharmaceutical compositions containing said polysaccharides |
| 08/29/2001 | EP0751709B1 Use of bcl-2 for the manufacture of medicaments for the therapeutic treatment and prevention of diseases |
| 08/29/2001 | EP0730473B1 Hirudin conjugates from hirudin and lipophilic compounds |
| 08/29/2001 | CN1310708A Substituted phenylamidines with antithrombotic action |
| 08/29/2001 | CN1310018A Compound gingko leaf preparation and its making process |
| 08/29/2001 | CN1310009A Medicine for treating leucocytopenia caused by lupus erythematosus |
| 08/29/2001 | CN1310006A Medicine for treating purpura caused by lupus erythematosus and other immunological disease |
| 08/29/2001 | CN1310000A Combined Chinese and Western medicine for treating cardiopulmonary disease in catabasis |
| 08/29/2001 | CN1309982A Orally taken hemostatic Chinese medicine |
| 08/29/2001 | CN1309977A Medicine for treating thrombus and rheumatism |
| 08/29/2001 | CN1070073C Medicine for treating hypercoagulable blood and its preparation |
| 08/29/2001 | CA2337661A1 Stabilized granulocyte colony stimulating factor |
| 08/28/2001 | US6281363 Antiinflammatory agents; antiarthritic agents; autoimmune disorders |
| 08/28/2001 | US6281352 Antiinflammatory agents |
| 08/28/2001 | US6281230 Isoindolines, method of use, and pharmaceutical compositions |
| 08/28/2001 | US6281206 Amidino and benzamidino compounds |
| 08/28/2001 | US6281175 Medical emulsion for lubrication and delivery of drugs |
| 08/28/2001 | US6281000 Dna fragment cloning into genome of recombinant adenoviral plasmid vector; human gene therapy |
| 08/28/2001 | US6280969 Growth arrest homeobox gene |
| 08/28/2001 | US6280959 Zinc chelated cell surface receptor ligands for use as agonist of dimeric cell surface receptors; for example, 2-bis(2,5-bis(2-benzimidazolylimino)-3A,6A-diphenyl-1,2,3,3a, 4,5,6,6a-octahydroimidazo(4,5-d)imidazole-N,N')-zinc(II) |
| 08/28/2001 | US6280729 Treating christmas disease in patient by administering effective amount of therapeutic composition comprising storage stable aqueous solution of purified factor ix |
| 08/28/2001 | US6280727 Hemostatic composition comprising thrombin and microfibrillar collagen in aqueous medium |
| 08/28/2001 | US6280724 Composition and method for preserving progenitor cells |
| 08/28/2001 | CA1341286C Blood substitutes |
| 08/23/2001 | WO2001061009A2 Polypeptides and nucleic acids encoding same |
| 08/23/2001 | WO2001060822A1 Amino acid derivatives and use thereof as nep, ace and ece inhibitors |
| 08/23/2001 | WO2001060821A1 Novel biarylcarboxamides |
| 08/23/2001 | WO2001060813A1 Beta-alanine derivatives and their use as receptor antagonists |
| 08/23/2001 | WO2001060798A1 Amine derivatives for the treatment of apoptosis |
| 08/23/2001 | WO2001060414A2 Genetic modification of the lung as a portal for gene delivery |
| 08/23/2001 | WO2001060412A2 Modification of biopolymers for improved drug delivery |
| 08/23/2001 | WO2001060394A1 Stable, nasally, orally or sublingually applicable pharmaceutical preparation |
| 08/23/2001 | WO2001060392A1 Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
| 08/23/2001 | WO2001060388A1 Cell activator |
| 08/23/2001 | WO2001060355A1 Modulation of bone formation |
| 08/23/2001 | WO2001060179A1 Improvements in or relating to solubilisation of flavonols |
| 08/23/2001 | WO2001025422A3 Antisense compositions and cancer-treatment methods |
| 08/23/2001 | WO2001012775A3 25 human secreted proteins |
| 08/23/2001 | WO2001010892A3 Peptide antagonists of factor VIIA |
| 08/23/2001 | WO2001010816A3 Substituted 2-dialkylaminoalkylbiphenyl derivatives |
| 08/23/2001 | WO2001007436A3 Substituted oxoazaheterocyclyl compounds |
| 08/23/2001 | WO2000071508A3 Inhibitors of factor Xa |
| 08/23/2001 | US20010016586 Use of organic compounds |
| 08/23/2001 | US20010016568 Zinc chelate dimeric cell surface receptor antagonist |
| 08/23/2001 | US20010016191 Viewing informatoin, selecting a site for, and preparing a molecule of an alteration on a granulocyte colony-stimulating factor (g-csf) three dimensional molecule, and testing for desired characteristics; retain internal core helices |
| 08/23/2001 | DE10005631A1 Arginin-Mimetika als Faktor X¶a¶-Inhibitoren Arginine mimetics as inhibitors of factor X¶a¶ |
| 08/23/2001 | CA2400634A1 Genetic modification of the lung as a portal for gene delivery |
| 08/23/2001 | CA2400631A1 Beta-alanine derivatives and their use as receptor antagonists |
| 08/23/2001 | CA2400537A1 Amino acid derivatives and use thereof as nep, ace and ece inhibitors |
| 08/23/2001 | CA2400374A1 Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
| 08/23/2001 | CA2400360A1 Polypeptides and nucleic acids encoding same |
| 08/23/2001 | CA2400205A1 Modification of biopolymers for improved drug delivery |
| 08/23/2001 | CA2399822A1 Stable, nasally, orally or sublingually applicable pharmaceutical preparation |
| 08/23/2001 | CA2399810A1 Modulation of bone formation |
| 08/23/2001 | CA2397651A1 Amine derivatives for the treatment of apoptosis |
| 08/23/2001 | CA2397458A1 Improvements in or relating to solubilisation of flavonols |
| 08/23/2001 | CA2397233A1 Biarylcarboxamides |
| 08/22/2001 | EP1125977A1 Dermatan sulfate composition as antithrombotic |
| 08/22/2001 | EP1125925A1 Amine derivatives for the treatment of apoptosis |
| 08/22/2001 | EP1125580A2 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors |
| 08/22/2001 | EP1125579A2 Uses of agrp-melanocortin receptor binding modulating compounds |
| 08/22/2001 | EP1124982A1 THE HEMATOPOIETIC, MYELOPROTECTING, ANTITUMOR IMMUNE CELLS GENERATING AND RADIOSENSITIZING POLYSACCHARIDE ISOLATED FROM i PANAX GINSENG /i |
| 08/22/2001 | EP1124961A2 Thrombopoietic compounds |
| 08/22/2001 | EP1124959A1 Cell surface molecule-induced macrophage activation |
| 08/22/2001 | EP1124856A1 Conformation-specific anti-von willebrand factor antibodies |
| 08/22/2001 | EP1124850A1 12 human secreted proteins |
| 08/22/2001 | EP1124824A1 Chromenone and chromanone derivatives as integrin inhibitors |
| 08/22/2001 | EP1124823A1 Thrombin inhibitors |
| 08/22/2001 | EP1124822A1 Thrombin inhibitors |
| 08/22/2001 | EP1124814A1 Aromatic derivatives and iron complexes thereof for the use as normalising agents of the iron level |
| 08/22/2001 | EP1124583A1 Adeno-associated vectors for expression of factor viii by target cells |
| 08/22/2001 | EP1124572A2 Genes and proteins predictive and therapeutic for renal disease and associated disorders |
| 08/22/2001 | EP1124567A2 Buffered compositions for dialysis |